Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 5,000 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David Watson sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $20.06, for a total value of $100,300.00. Following the completion of the sale, the general counsel directly owned 108,730 shares in the company, valued at approximately $2,181,123.80. The trade was a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Apellis Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ APLS opened at $19.73 on Wednesday. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The business has a 50-day moving average of $23.62 and a 200-day moving average of $21.87. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of 63.65 and a beta of 0.70. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $35.72.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. During the same period in the previous year, the business posted ($0.46) earnings per share. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% on a year-over-year basis. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on APLS shares. Royal Bank Of Canada upped their target price on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Friday, August 1st. Cantor Fitzgerald increased their price objective on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Wolfe Research initiated coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They issued a “peer perform” rating for the company. Finally, Wells Fargo & Company initiated coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They set an “overweight” rating and a $32.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $33.06.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in APLS. Assetmark Inc. grew its holdings in Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after acquiring an additional 1,221 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after purchasing an additional 1,373 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Apellis Pharmaceuticals during the 3rd quarter valued at about $64,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).